Bright Minds Biosciences DRUG 深 沪
等待开盘 04-02 09:30:00 美东时间
71.72
-1.250
-1.71%
华盛通- 最 高75.99
- 今 开74.68
- 成交量 22.49万股
- 最 低 69.245
- 昨 收 72.97
- 总市值 7.02亿
- 52周最高 123.75
- 市盈率 静 --
- 换手率 2.30%
- 52周最低 23.175
- 委 比 -72.05%
- 总股本 978.72万
- 历史最高 123.75
- 量 比 1.33
- 振 幅 9.24%
- 历史最低 0.93
- 每 手 1
- 风险率 21.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target
BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
03-30 17:57
'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment
https://www.marijuanamoment.net/bipartisan-senators-file-bill-to-support-psychedelics-research-and-treatment-for-veterans/
03-28 01:28
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
HC Wainwright & Co. Maintains Buy on Bright Minds Biosciences, Raises Price Target to $145
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and raises the price target from $115 to $145.
03-05 00:04
Bright Minds Biosciences to Present at Upcoming Conferences
Bright Minds Biosciences, Inc., a biotech company focusing on developing highly selective 5-HT2 agonists for treating drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders, will present at three upcoming conferences: TD Cowen Health Care Conference (March 4, 9:10am ET, webcast available), Leerink Partners Global Healthcare Conference (March 9, no webcast), and Jefferies Biotech on the Beach (March 10, 1x1 meetings).
02-25 21:30
美股大行评级 | 潜在涨幅1226.53%！RenovoRx获Ascendiant Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从12.5美元升至13美元；Lake Street：维持Insight Molecular"买入"评级，目标价从8美元升至12美元
02-18 16:48
BTIG Maintains Buy on Bright Minds Biosciences, Maintains $147 Price Target
BTIG analyst Thomas Shrader maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
02-17 19:00
Bright Minds Biosciences Reports Q4 Net Loss of CAD 7.57 Million
Bright Minds Biosciences Reports Q4 Net Loss of CAD 7.57 Million Bright Minds Biosciences Inc. reported its earnings for the three months ended December 31, 2025. The company posted a net and comprehensive loss of CAD 7.57 million for the quarter. Basic and diluted loss per share stood at CAD 0.97.
02-13 19:07
Bright Minds prices $175M stock offering
Bright Minds Biosciences (DRUG) priced its previously announced public offering of ~1.95M shares at a price of $90.00 per share. Gross proceeds are expected to be ~$175M. The underwriters have a 30-da...
01-08 15:29
